Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03742102
Title A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Oleclumab + Paclitaxel

Durvalumab + Trastuzumab deruxtecan

Durvalumab + Paclitaxel

Capivasertib + Durvalumab + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.